Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer.

ABSTRACT: Over the past decade, immunotherapy has demonstrated an impressive improvement in treatment outcomes for multiple cancers. Following the landmark approvals for use of immune checkpoint inhibitors, new challenges emerged in various clinical settings. Not all tumor types harbor immunogenic characteristics capable of triggering responses. Similarly, many tumors' immune microenvironment allows them to become evasive, leading to resistance and, thus, limiting the durability of responses. To overcome this limitation, new T-cell redirecting strategies such as bispecific T-cell engager (BiTE) have become attractive and promising immunotherapies. Our review provides a comprehensive perspective of the current evidence of BiTE therapies in solid tumors. Considering that immunotherapy has shown modest

SUBMITTER: Simao DC 

PROVIDER: S-EPMC10001031 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature